News
Oncoinvent Appoints Oystein Soug as CEO
New CEO brings over 15 years of proven leadership experience, including deep expertise growing international radiopharmaceutical companies.
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer
Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer.
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
Newly elected members of Board of Directors consist of internationally merited business and clinical leaders
Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients
Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer
IND clearance is now obtained for both lead indications for Radspherin®
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients
This marks the first IND clearance for initiation of Radspherin® clinical trials in the US
Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences
Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed
Presentation on September 30, 2023
Oncoinvent appoints Anders Månsson as CEO
Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.
Oncoinvent to Present at TD Cowen Radiopharmaceutical Innovation Summit
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting
Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences
All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported
Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer
Poster discussion session on June 5, 2023 at 1:15 p.m. ET
Information from Oncoinvent AS regarding the newly elected board members and the resignation of CEO Jan Alfheim
Oncoinvent shareholders have recently elected new board members and the board now comprises Roy Larsen (Executive Chairman), Øyvind Bruland, Petter Fjellstad, Thora Jonasdottir, Anne Cecilie Alvik and Mona-Elisabeth Revheim.
Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes
Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
Oncoinvent updates: Phase I dose escalation completed successfully in two indications Phase 2 A inclusion has started
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals. Further updates will be provided in an upcoming investor conference call.
Oncoinvent initiates Radspherin® phase 2A trial
First patient has been treated in the RAD-18-002 phase 2A clinical study
Data from the ongoing Radspherin® RAD-18-002 phase 1 trial in colorectal cancer patients to be presented at the 2022 ASCO Annual Meeting
All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.
Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer
Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.
Oncoinvent to Participate in Upcoming Virtual Investor Conferences
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors
Company adds experienced clinical development expert to its board of directors
Oncoinvent announces completion of enrollment in the RAD-18-002 phase 1 clinical study
Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.
Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine
Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate
Oncoinvent Strengthens Leadership Team
The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials
Oncoinvent Announces Advancement of Radspherin® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort
Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round
Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®
Following a year of outstanding performance, Oncoinvent aims to raise NOK 150 -200 million to move into efficacy studies with Radspherin®
Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Platinum Sensitive Recurrent Ovarian Cancer Patients with Peritoneal Carcinomatosis
Safety Monitoring Committee review of second dose-level cohort allows advancement of Phase 1 RAD-18-001 study to third cohort dose level cohort
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort
Oncoinvent Announces Advancement of Radspherin® to Second Dose Level Cohort in Ongoing Phase 1 Trial
Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent Advances Radspherin® to Second Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.
Oncoinvent announces result of oversubscribed repair issue
Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Press Release 02.2020:
Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin®.
Oncoinvent Secures 40 Million NOK Financing Round Led by Hadean Ventures
Press Release 01.2020
Oncoinvent AS today announced it has completed a 40 million NOK round of financing. Hadean Ventures led the investment round with participation from existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS. The investment brings Oncoinvent’s total funding to 268 million NOK and will help the company aggressively pursue clinical development of its lead product candidate Radspherin®. Dr. Ingrid Teigland Akay, Managing Partner of Hadean Ventures will join the Oncoinvent Board of Directors.
Oncoinvent: Publication of standardization model for activity of radium-224
Press Release 05.2019: Oncoinvent announced today that research relating to a radioactivity standard for radium-224 (224Ra) in secular equilibrium has been published in the Journal of Applied Radiation and Isotopes by Oncoinvent research scientist Elisa Napoli and researchers from the National Institute of Standards and Technology (NIST). This is an important step in the development of Radspherin® as the standard will form the basis for calibration of clinical doses of Radspherin®.
Oncoinvent awarded 4,6 MNOK in Innovation Funding
Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.
Oncoinvent receives manufacturing authorization for clinical trial material
Press Release 03.2019: Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial material from the Norwegian Medicine Agency.
Oncoinvent signs distribution agreement with radiopharmaceutical wholesaler
Press Release 02.2019: Oncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal products) to sites and institutions as part of the company’s clinical trial program.
Oncoinvent announces appointment of new Chief Financial Officer
Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.
Oncoinvent to present and attend the 32nd Annual Congress of the European Association of Nuclear Medicine
Press Release 07.2018. Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).
Oncoinvent researcher presents findings at SNMMI annual meeting in Philadelphia
Press Release 06.2018: Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday morning Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA.
Oncoinvent to receive 12 MNOK in BIA funding from the Research Council of Norway
Press Release 05.2018: Oncoinvent is pleased to announce today that it has fulfilled the necessary requirements stipulated by the Research Council of Norway and is now eligible to receive 12 MNOK in BIA project funding to help develop its lead product Radspherin®.
Oncoinvent sets regulatory strategy for development of Radspherin®
Press Release 04.2018: Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.
Oncoinvent publishes data explaining Radspherin® `s mechanism of action
Press Release 03.2018: Oncoinvent publishes data explaining Radspherin® `s mechanism of action
Oncoinvent selected to receive BIA funding from the Research Council of Norway
Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.
New Radspherin® data published
Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.
Opening of the Radspherin® Production and Laboratory Facility
Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.
Radspherin® EU patent and OI-3 antibody US patent issued
Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)
Press Release 06.2017
Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.
Oncoinvent: A novel method for making 212Pb-labeled monoclonal antibodies using a novel 224Ra-based generator solution
Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.
Oncoinvent Strengthens Management and Research Teams
Press Release 04.2017: Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the company
Oncoinvent closes $ 25 Million Private Placement
Press Release 03.2017: Financing will support development of Radspherin®, a novel radiotherapeutic treatment for peritoneal carcinomatosis
Oncoinvent is on the move!
Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.
Oncoinvent patent issues in the USA
Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
DnB Healthcare Prize 2016
Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.
New Chief Executive Officer
The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific
New board members at Oncoinvent as
The extraordinary General Assembly of Oncoinvent convened at July 28th unanimously decided to elect Ludvik Sandnes and Jónas Einarsson as new members of the Board of Directors.
15 million in a private placement
Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.
Oncoinvent Appoints Oystein Soug as CEO
New CEO brings over 15 years of proven leadership experience, including deep expertise growing international radiopharmaceutical companies.
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer
Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer.
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
Newly elected members of Board of Directors consist of internationally merited business and clinical leaders
Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients
Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer
IND clearance is now obtained for both lead indications for Radspherin®
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients
This marks the first IND clearance for initiation of Radspherin® clinical trials in the US
Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences
Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed
Presentation on September 30, 2023
Oncoinvent appoints Anders Månsson as CEO
Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.
Oncoinvent to Present at TD Cowen Radiopharmaceutical Innovation Summit
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting
Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences
All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported
Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer
Poster discussion session on June 5, 2023 at 1:15 p.m. ET
Information from Oncoinvent AS regarding the newly elected board members and the resignation of CEO Jan Alfheim
Oncoinvent shareholders have recently elected new board members and the board now comprises Roy Larsen (Executive Chairman), Øyvind Bruland, Petter Fjellstad, Thora Jonasdottir, Anne Cecilie Alvik and Mona-Elisabeth Revheim.
Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes
Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
Oncoinvent updates: Phase I dose escalation completed successfully in two indications Phase 2 A inclusion has started
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals. Further updates will be provided in an upcoming investor conference call.
Oncoinvent initiates Radspherin® phase 2A trial
First patient has been treated in the RAD-18-002 phase 2A clinical study
Data from the ongoing Radspherin® RAD-18-002 phase 1 trial in colorectal cancer patients to be presented at the 2022 ASCO Annual Meeting
All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.
Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer
Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.
Oncoinvent to Participate in Upcoming Virtual Investor Conferences
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors
Company adds experienced clinical development expert to its board of directors
Oncoinvent announces completion of enrollment in the RAD-18-002 phase 1 clinical study
Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.
Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine
Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate
Oncoinvent Strengthens Leadership Team
The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials
Oncoinvent Announces Advancement of Radspherin® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort
Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round
Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®
Following a year of outstanding performance, Oncoinvent aims to raise NOK 150 -200 million to move into efficacy studies with Radspherin®
Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Platinum Sensitive Recurrent Ovarian Cancer Patients with Peritoneal Carcinomatosis
Safety Monitoring Committee review of second dose-level cohort allows advancement of Phase 1 RAD-18-001 study to third cohort dose level cohort
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort
Oncoinvent Announces Advancement of Radspherin® to Second Dose Level Cohort in Ongoing Phase 1 Trial
Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent Advances Radspherin® to Second Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.
Oncoinvent announces result of oversubscribed repair issue
Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Press Release 02.2020:
Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin®.
Oncoinvent Secures 40 Million NOK Financing Round Led by Hadean Ventures
Press Release 01.2020
Oncoinvent AS today announced it has completed a 40 million NOK round of financing. Hadean Ventures led the investment round with participation from existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS. The investment brings Oncoinvent’s total funding to 268 million NOK and will help the company aggressively pursue clinical development of its lead product candidate Radspherin®. Dr. Ingrid Teigland Akay, Managing Partner of Hadean Ventures will join the Oncoinvent Board of Directors.
Oncoinvent: Publication of standardization model for activity of radium-224
Press Release 05.2019: Oncoinvent announced today that research relating to a radioactivity standard for radium-224 (224Ra) in secular equilibrium has been published in the Journal of Applied Radiation and Isotopes by Oncoinvent research scientist Elisa Napoli and researchers from the National Institute of Standards and Technology (NIST). This is an important step in the development of Radspherin® as the standard will form the basis for calibration of clinical doses of Radspherin®.
Oncoinvent awarded 4,6 MNOK in Innovation Funding
Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.
Oncoinvent receives manufacturing authorization for clinical trial material
Press Release 03.2019: Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial material from the Norwegian Medicine Agency.
Oncoinvent signs distribution agreement with radiopharmaceutical wholesaler
Press Release 02.2019: Oncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal products) to sites and institutions as part of the company’s clinical trial program.
Oncoinvent announces appointment of new Chief Financial Officer
Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.
Oncoinvent to present and attend the 32nd Annual Congress of the European Association of Nuclear Medicine
Press Release 07.2018. Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).
Oncoinvent researcher presents findings at SNMMI annual meeting in Philadelphia
Press Release 06.2018: Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday morning Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA.
Oncoinvent to receive 12 MNOK in BIA funding from the Research Council of Norway
Press Release 05.2018: Oncoinvent is pleased to announce today that it has fulfilled the necessary requirements stipulated by the Research Council of Norway and is now eligible to receive 12 MNOK in BIA project funding to help develop its lead product Radspherin®.
Oncoinvent sets regulatory strategy for development of Radspherin®
Press Release 04.2018: Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.
Oncoinvent publishes data explaining Radspherin® `s mechanism of action
Press Release 03.2018: Oncoinvent publishes data explaining Radspherin® `s mechanism of action
Oncoinvent selected to receive BIA funding from the Research Council of Norway
Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.
New Radspherin® data published
Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.
Opening of the Radspherin® Production and Laboratory Facility
Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.
Radspherin® EU patent and OI-3 antibody US patent issued
Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)
Press Release 06.2017
Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.
Oncoinvent: A novel method for making 212Pb-labeled monoclonal antibodies using a novel 224Ra-based generator solution
Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.
Oncoinvent Strengthens Management and Research Teams
Press Release 04.2017: Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the company
Oncoinvent closes $ 25 Million Private Placement
Press Release 03.2017: Financing will support development of Radspherin®, a novel radiotherapeutic treatment for peritoneal carcinomatosis
Oncoinvent is on the move!
Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.
Oncoinvent patent issues in the USA
Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
DnB Healthcare Prize 2016
Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.
New Chief Executive Officer
The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific
New board members at Oncoinvent as
The extraordinary General Assembly of Oncoinvent convened at July 28th unanimously decided to elect Ludvik Sandnes and Jónas Einarsson as new members of the Board of Directors.
15 million in a private placement
Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.
Oncoinvent Appoints Oystein Soug as CEO
New CEO brings over 15 years of proven leadership experience, including deep expertise growing international radiopharmaceutical companies.
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer
Oncoinvent ASA, a clinical stage radiopharmaceutical company advancing alpha emitter therapy across a variety of peritoneal metastases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Radspherin® for the treatment of patients with peritoneal metastases from ovarian cancer.
Oncoinvent to Present at Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the Cantor Fitzgerald Frontiers in Radiopharma Virtual Summit on Monday, May 20, 2024 at 9:00 a.m. ET.
Oncoinvent Announces Changes to its Board of Directors and Formation of Scientific and Clinical Advisory Board
Newly elected members of Board of Directors consist of internationally merited business and clinical leaders
Formation of Scientific and Clinical Advisory Board leverages expertise of renowned Oncoinvent founders to support pipeline advancement
Oncoinvent to Present at Evercore ISI 2024 Emerging Biotech Conference
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients
Progressing to study Radspherin® in the first-line treatment setting for ovarian cancer
IND clearance is now obtained for both lead indications for Radspherin®
Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients
This marks the first IND clearance for initiation of Radspherin® clinical trials in the US
Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies
At 18 months, no patients at the recommended dose of 7 MBq experienced peritoneal recurrences
Robust safety profile demonstrated, no serious adverse events related to Radspherin® reported
Presentation on October 4, 2023, at 11:55 a.m. CET (5:55 a.m. EDT)
Oncoinvent To Present Initial Safety Data from the Phase 1 Trial of Radspherin® in Ovarian Cancer Patients at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
Recommended dose of 7 MBq established following completion of dose escalation; no dose-limiting toxicity observed
Presentation on September 30, 2023
Oncoinvent appoints Anders Månsson as CEO
Anders brings nearly 30 years of international and diverse experience in oncology-focused drug development and commercialization.
Oncoinvent to Present at TD Cowen Radiopharmaceutical Innovation Summit
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that members of management will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.
Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting
Median PFS (progression free survival) was not reached at 15 months, and no patients at recommended dose of 7 MBq had peritoneal recurrences
All dose levels of Radspherin®, including recommended dose of 7 MBq, were well tolerated at 15 months with no serious adverse events related to Radspherin® reported
Radspherin® is currently being evaluated in two ongoing Phase 1/2A trials for the treatment of peritoneal carcinomatosis from colorectal cancer and ovarian cancer
Poster discussion session on June 5, 2023 at 1:15 p.m. ET
Information from Oncoinvent AS regarding the newly elected board members and the resignation of CEO Jan Alfheim
Oncoinvent shareholders have recently elected new board members and the board now comprises Roy Larsen (Executive Chairman), Øyvind Bruland, Petter Fjellstad, Thora Jonasdottir, Anne Cecilie Alvik and Mona-Elisabeth Revheim.
Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes
Publications highlight the safety and tolerability of Radspherin® for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.
Oncoinvent updates: Phase I dose escalation completed successfully in two indications Phase 2 A inclusion has started
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced strong progress with clinical trials, including patient recruitment and efficacy signals. Further updates will be provided in an upcoming investor conference call.
Oncoinvent initiates Radspherin® phase 2A trial
First patient has been treated in the RAD-18-002 phase 2A clinical study
Data from the ongoing Radspherin® RAD-18-002 phase 1 trial in colorectal cancer patients to be presented at the 2022 ASCO Annual Meeting
All dose levels of Radspherin® were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study.
Radspherin® is currently being evaluated in two ongoing Phase 1 trials for the treatment of peritoneal carcinomatosis from ovarian cancer and colorectal cancer
Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim Radiopharmaceuticals Day on Tuesday, May 17, 2022 in New York, NY.
Oncoinvent to Participate in Upcoming Virtual Investor Conferences
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:
Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors
Company adds experienced clinical development expert to its board of directors
Oncoinvent announces completion of enrollment in the RAD-18-002 phase 1 clinical study
Twenty-three colorectal cancer patients in total have been enrolled in the Radspherin® RAD-18-002 phase 1 clinical trial and treated with Radspherin®. No SAE’s related to the Radspherin® treatment have been observed.
Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine
Oncoinvent presents preclinical dosimetry data documenting a therapeutic relevant biodistribution of Radspherin® as well as preclinical data on the potential synergistic effects of Radspherin® with existing cancer therapies. The company also will present preclinical results of a novel 212Pb product candidate
Oncoinvent Strengthens Leadership Team
The company makes three important new appointments to the clinical and regulatory teams in preparation for the upcoming Radspherin® phase 2 clinical trials
Oncoinvent Announces Advancement of Radspherin® to Fourth Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Ovarian Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort
Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round
Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®
Following a year of outstanding performance, Oncoinvent aims to raise NOK 150 -200 million to move into efficacy studies with Radspherin®
Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®
Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study
Oncoinvent Announces Progression of Radspherin® to Third Dose Level Cohort in Ongoing RAD-18-001 Phase 1 Trial in Platinum Sensitive Recurrent Ovarian Cancer Patients with Peritoneal Carcinomatosis
Safety Monitoring Committee review of second dose-level cohort allows advancement of Phase 1 RAD-18-001 study to third cohort dose level cohort
Oncoinvent Announces Advancement of Radspherin® to Final Dose Level Cohort in Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients
Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort
Oncoinvent Announces Advancement of Radspherin® to Second Dose Level Cohort in Ongoing Phase 1 Trial
Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort
Oncoinvent Advances Radspherin® to Third Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent Advances Radspherin® to Second Dose Level in Ongoing Phase 1 Clinical Trial
Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.
Oncoinvent announces result of oversubscribed repair issue
Reference is made to the extraordinary general meeting notice published on 20th of May 2020 regarding a repair issue with gross proceeds of up to NOK 9 million directed towards eligible shareholders and company employees (the “Repair Issue”). The Repair Issue consisted of an offer of minimum 1 and maximum 175,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible shareholders and an offer of minimum 1 and maximum 25,000 new shares (each an “Offer Share”) in Oncoinvent AS to eligible employees. The subscription period for the Repair Issue ended on 29th of May 2020 at 16.30 hours (CEST). The subscription price in the Repair Issue was NOK 45 per Offer Share.
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Press Release 02.2020:
Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosis
Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin®.
Oncoinvent Secures 40 Million NOK Financing Round Led by Hadean Ventures
Press Release 01.2020
Oncoinvent AS today announced it has completed a 40 million NOK round of financing. Hadean Ventures led the investment round with participation from existing investors CGS Holding AS, Helene Sundt AS, Alpine Capital AS, Artal AS, and Sciencons AS. The investment brings Oncoinvent’s total funding to 268 million NOK and will help the company aggressively pursue clinical development of its lead product candidate Radspherin®. Dr. Ingrid Teigland Akay, Managing Partner of Hadean Ventures will join the Oncoinvent Board of Directors.
Oncoinvent: Publication of standardization model for activity of radium-224
Press Release 05.2019: Oncoinvent announced today that research relating to a radioactivity standard for radium-224 (224Ra) in secular equilibrium has been published in the Journal of Applied Radiation and Isotopes by Oncoinvent research scientist Elisa Napoli and researchers from the National Institute of Standards and Technology (NIST). This is an important step in the development of Radspherin® as the standard will form the basis for calibration of clinical doses of Radspherin®.
Oncoinvent awarded 4,6 MNOK in Innovation Funding
Press Release 04.2019: Oncoinvent is pleased to announce that the Oslo University Hospital and Oncoinvent have each been awarded Innovation Funding to develop Radspherin® as a treatment for colorectal cancer patients suffering from peritoneal carcinomatosis. The two awards make for a combined total of 7,9 million NOK where Oncoinvent will receive 4,6 MNOK and Oslo University Hospital 3,3 MNOK. The Innovation Norway grants will allow Oncoinvent to expand the clinical use of Radspherin® from the current planned study in ovarian cancer patients and enables the company to carry out phase 1 clinical trials to assess the clinical safety of Radspherin® in colorectal cancer patients as well.
Oncoinvent receives manufacturing authorization for clinical trial material
Press Release 03.2019: Oncoinvent is pleased to announce that it has received a manufacturing authorization (GMP certificate) for production of Radspherin® clinical trial material from the Norwegian Medicine Agency.
Oncoinvent signs distribution agreement with radiopharmaceutical wholesaler
Press Release 02.2019: Oncoinvent has signed an agreement with the Institute of Energy Technology (IFE) for the distribution of Radspherin (investigational medicinal products) to sites and institutions as part of the company’s clinical trial program.
Oncoinvent announces appointment of new Chief Financial Officer
Press Release 02.2019. Oncoinvent is pleased to announce it has appointed Tore Kvam as Chief Financial Officer. Mr. Kvam has a extensive experience as CFO with several years also within the life science industry. He holds an MBA from the Norwegian Business School, BI and is a Certified European Financial Analyst (CEFA) from the Norwegian School of Economics.
Oncoinvent to present and attend the 32nd Annual Congress of the European Association of Nuclear Medicine
Press Release 07.2018. Oncoinvent announces that Radspherin® research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).
Oncoinvent researcher presents findings at SNMMI annual meeting in Philadelphia
Press Release 06.2018: Oncoinvent is pleased to announce that research scientist Elisa Napoli presented Radspherin® research findings earlier this week during the Monday morning Novel Radiochemistry session at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Philadelphia, USA.
Oncoinvent to receive 12 MNOK in BIA funding from the Research Council of Norway
Press Release 05.2018: Oncoinvent is pleased to announce today that it has fulfilled the necessary requirements stipulated by the Research Council of Norway and is now eligible to receive 12 MNOK in BIA project funding to help develop its lead product Radspherin®.
Oncoinvent sets regulatory strategy for development of Radspherin®
Press Release 04.2018: Oncoinvent announced today that the regulatory strategy that will be used in the development of its lead product Radspherin® has been selected.
Oncoinvent publishes data explaining Radspherin® `s mechanism of action
Press Release 03.2018: Oncoinvent publishes data explaining Radspherin® `s mechanism of action
Oncoinvent selected to receive BIA funding from the Research Council of Norway
Press Release 02.2018: Oncoinvent is pleased to announce today that Oncoinvent has been selected to receive BIA project funding from the Research Council of Norway to help develop its lead product Radspherin®.
New Radspherin® data published
Press Release 01.2018: Oncoinvent is pleased to announce today that Oncoinvent researchers have published data demonstrating the efficacy of the Radspherin® in two separate models of peritoneal carcinomatosis originating from ovarian cancer cell lines in the journal Translational Oncology.
Opening of the Radspherin® Production and Laboratory Facility
Press Release 08.2017: Oncoinvent held an opening ceremony for its new production and lab facilities today. A total of 40 guests attended the opening.
Radspherin® EU patent and OI-3 antibody US patent issued
Press Release: Oncoinvent announced today that European Patent 3111959 entitled ”Radiotherapeutic particles and suspensions” has issued. This patent provides patent protection for the company’s lead product candidate Radspherin® in Europe. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM)
Press Release 06.2017
Work presented indicates that, with certain precautions, 224Ra based biomedical products can be used in a safe manner for the hospital staff and patients.
In vivo studies show that 224Ra-labeled CaCO3 microparticles could be safely administered in mice at therapeutically relevant doses and with a high degree of intraperitoneal retention.
The novel α-emitting microparticles have properties that make them a promising new modality for intracavitary cancer therapy.
Oncoinvent: A novel method for making 212Pb-labeled monoclonal antibodies using a novel 224Ra-based generator solution
Press Release 05.2017: Oncoinvent researchers collaborate to develop a system to generate alpha-particle releasing radioimmunoconjugates that may be simpler and less time-consuming compared with current established methods used in clinical trials.
Oncoinvent Strengthens Management and Research Teams
Press Release 04.2017: Key positions to assist in the development and commercialization of Radspherin® have been filled, bringing valuable expertise and experience to the company
Oncoinvent closes $ 25 Million Private Placement
Press Release 03.2017: Financing will support development of Radspherin®, a novel radiotherapeutic treatment for peritoneal carcinomatosis
Oncoinvent is on the move!
Oncoinvent announced today that will be moving operations from its current facilities at Kjelsåsveien 168B to a new location at Gullhaugveien 7 in Nydalen, Oslo in April. The move will provide the company with a larger office space as well as space for a new production and lab facililties.
Oncoinvent patent issues in the USA
Press release: Oncoinvent announced today that US Patent 9,539,346 entitled “Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer.
DnB Healthcare Prize 2016
Press release: Oncoinvent selected to present as a finalist in DnB Healthcare Prize 2016 competition.
New Chief Executive Officer
The 1st of September 2016, Jan A. Alfheim entered the position as Chief Executive Officer (CEO) of Oncoinvent AS. Jan A. Alfheim comes from the position Chief Operation Officer (COO) in Nordic Nanovector ASA, where he until 2014 was responsible for the company’s leadership as CEO. Tina B. Bønsdorff enters the position as Chief Scientific
New board members at Oncoinvent as
The extraordinary General Assembly of Oncoinvent convened at July 28th unanimously decided to elect Ludvik Sandnes and Jónas Einarsson as new members of the Board of Directors.
15 million in a private placement
Oncoinvent AS has successfully completed a private placement. The share offering was directed towards Oncoinvent’s existing shareholders and a limited number of private investors. The issue was oversubscribed and will provide NOK 15 mill. to Oncoinvent, net of transaction costs.
